Catheter-DCM, 2014 trial summary

A randomised clinical trial investigating the effect of ixmyelocel-T versus control in patients with dilated cardiomyopathy

NCT01020968    Circ Res 2014;115:730-7  




Studied treatment ixmyelocel-T: an expanded, autologous multi-cellular therapy
Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) administered via catheter
Control treatment



Patients patients with dilated cardiomyopathy
Group sizes -9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI all-cause mortality - -9 - -9 no data acute heart failure - -9 - -9 no data ventricular tachycardia - -9 - -9 no data NYHA deterioration - -9 - -9 no data cardiac event - -9 - -9 no data0,22,01,0


Henry TD, Traverse JH, Hammon BL, East CA, Bruckner B, Remmers AE, Recker D, Bull DA, Patel AN Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res 2014;115:730-7     [PMID: 25142002]   link to pdf  



Registering number NCT01020968 (see trial on clinicaltrials.gov)
Code Name

 




Appears in following systematic reviews: